title: Biology-driven phase II trials: what is the optimal model for molecular selection?
authors.affiliation: L'Institut National de la Santé et de la Recherche Médicale U981, Institut Gustave Roussy, Villejuif, France.
authors.forename: Fabrice
authors.initials: F
authors.lastname: Andre
authors.forename: Suzette
authors.initials: S
authors.lastname: Delaloge
authors.forename: Jean-Charles
authors.initials: JC
authors.lastname: Soria
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001681:Biological Assay; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D017322:Clinical Trials, Phase II as Topic / Q000379:methods*; D005820:Genetic Testing; D057166:High-Throughput Screening Assays; D006801:Humans; D008954:Models, Biological; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D018579:Patient Selection; D015398:Signal Transduction / Q000187:drug effects* / Q000235:genetics; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor